Endo Diversification Leads to Indevus Buyout
Taskin Ahmed
Abstract
Endo Pharmaceuticals, the marketer of pain medications, has reached an agreement to acquire Indevus Pharmaceuticals in a deal that is intended to bolster its pipeline and expand its business beyond pain therapy. Indevus specialises in urology and endocrinology and has two products awaiting approval.
Full Text: pdf html
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.